On 11 November 2025, the UK government announced plans to phase out animal testing for drugs. This follows the US FDA's decision from earlier this year to reduce animal testing requirements for monoclonal antibodies and other therapies.

These regulatory shifts are more than policy changes. They represent recognition that two technologies, organoids and organ-on-a-chip systems, have matured enough to serve as viable alternatives to animal models in drug development.

Is artificial intelligence (AI) in biotech and pharma just hype, or are we seeing true breakthroughs in drug discovery? Headlines tout billion-dollar deals, supercomputers for research, and high success rates for AI-designed molecules. But as some AI biotechs collapse, the risks and results are less clear. Read on to see what the data says.

Discover how clear, scientifically accurate content for life science companies drives funding, leads, and conversion. Learn why life sciences companies invest in expert scientific communication and the measurable impact on research visibility and business growth.

Have you heard about “zombie” biotech companies? These are companies whose value becomes lower than their cash reserves. And there is a new breed of company , lurking in the shadow of innovation, ready to hunt biotechnology's most vulnerable targets. Read on to find out more about the economic battlefield shaping innovation in the biotech and pharma industries.

The global obesity “epidemic” has sparked a pharmaceutical transformation, with GLP-1 receptor agonists emerging as the most effective drugs for weight management. Learn more about how this started, the current players, and the future market forecast!

With students using ChatGPT to complete essays, the job market in tatters for entry-level scientists, and more and more investment on AI-biology research, what is the future of education in biology and related fields? Are we to stop students from using AI, to keep teaching them in the same way we have for so long? I say that is no longer possible.

The blood-brain barrier stands as one of evolution's most sophisticated achievements. After 111 years of failed attempts, two companies join to try to crack human biology's finest safe. Will they succeed, providing hope for millions of people living with neurodegenerative diseases?

In early 2025, a baby named KJ became the first person ever treated with a fully personalized CRISPR gene-editing therapy. Born with a rare, life-threatening disorder, KJ’s story is more than a medical miracle, it is a glimpse into a new era where cures for rare diseases could become reality for many more children.

Dive into the article to learn how that happened, with insights into the science and the ripples this case has had in the world of gene editing!